---
layout: default
title: Pegvisomant
parent: 僅模型預測 (L5)
nav_order: 606
evidence_level: L5
indication_count: 10
---

# Pegvisomant
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Pegvisomant: From Acromegaly to Borderline Ovarian Serous Tumor

## One-Sentence Summary

Pegvisomant is a growth hormone (GH) receptor antagonist originally developed to treat acromegaly by blocking GH/IGF-1 signaling.
The TxGNN model predicts it may show activity in **borderline ovarian serous tumor**, but this prediction currently has **no supporting clinical trials and no supporting literature** — it rests entirely on knowledge-graph inference.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Acromegaly (GH excess) — inferred from mechanism description; not separately confirmed in this evidence pack |
| Predicted New Indication | Borderline ovarian serous tumor |
| TxGNN Prediction Score | 98.63% |
| Evidence Level | L5 |
| Canada Market Status | Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed, sourced mechanism-of-action data is not available for this drug in the current evidence pack (`original_moa` is a data gap). Based on contextual information captured alongside the prediction, Pegvisomant acts as a **GH receptor antagonist**, blocking GH/IGF-1 signal transduction — this is consistent with its known clinical role in acromegaly.

The rationale linking this mechanism to borderline ovarian serous tumor is purely theoretical: the GH/IGF-1 axis has been proposed in the general oncology literature as a contributor to proliferation in some ovarian tumors, so a GH-axis antagonist is hypothesized to plausibly slow growth. However, no tumor-specific mechanistic study, preclinical data, or clinical evidence currently supports this link for this specific tumor subtype.

The evidence pack itself flags this explicitly: the model's high similarity score most likely reflects a **structural association** between GH/IGF-1-related nodes and tumor-related nodes in the knowledge graph, rather than a validated causal relationship. This should be treated as a hypothesis-generating signal only.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Canada Market Information

Pegvisomant is **not currently marketed in Canada** — no Drug Identification Numbers (DINs) are on record, and no license data is available in this evidence pack.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by a knowledge-graph inference (L5) with zero clinical trials and zero publications; the mechanistic link to this specific ovarian tumor subtype is speculative and unconfirmed. There is no basis to advance this candidate beyond hypothesis stage.

**To proceed, the following is needed:**
- TFDA/regulatory label warnings and contraindications (currently blocking — flagged as a critical data gap)
- Confirmed, sourced mechanism-of-action documentation (currently a data gap)
- Preclinical or in-vitro evidence specifically linking GH/IGF-1 antagonism to borderline ovarian serous tumor biology
- Any real-world case reports or registry signals, given the complete absence of trials and literature
- Confirmation of original approved indication(s), since no license/indication text was available in this evidence pack
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

